Context Therapeutics’ (CNTX) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Context Therapeutics (NASDAQ:CNTX) in a research report released on Friday morning,Benzinga reports. The brokerage currently has a $9.00 price target on the stock.

Several other brokerages have also recently issued reports on CNTX. HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of Context Therapeutics in a report on Friday. JMP Securities started coverage on shares of Context Therapeutics in a research note on Wednesday, January 8th. They set an “outperform” rating and a $4.00 price target for the company. Finally, Citizens Jmp upgraded shares of Context Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 8th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $6.17.

Context Therapeutics Trading Up 0.2 %

Shares of Context Therapeutics stock opened at $0.77 on Friday. The company has a fifty day simple moving average of $0.85 and a 200-day simple moving average of $1.44. Context Therapeutics has a 12-month low of $0.64 and a 12-month high of $2.75. The stock has a market cap of $57.88 million, a price-to-earnings ratio of -0.85 and a beta of 2.06.

Context Therapeutics (NASDAQ:CNTX) last issued its earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01. On average, analysts forecast that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Context Therapeutics

A number of large investors have recently bought and sold shares of the company. MPM Bioimpact LLC purchased a new position in Context Therapeutics during the 4th quarter worth $15,441,000. Blue Owl Capital Holdings LP raised its position in Context Therapeutics by 17.5% during the 4th quarter. Blue Owl Capital Holdings LP now owns 6,357,928 shares of the company’s stock worth $6,676,000 after buying an additional 946,638 shares during the last quarter. Franklin Resources Inc. raised its position in Context Therapeutics by 115.9% during the 4th quarter. Franklin Resources Inc. now owns 4,003,380 shares of the company’s stock worth $4,204,000 after buying an additional 2,149,392 shares during the last quarter. Allostery Investments LP purchased a new position in Context Therapeutics during the 4th quarter worth $998,000. Finally, Geode Capital Management LLC raised its position in Context Therapeutics by 9.2% during the 4th quarter. Geode Capital Management LLC now owns 628,729 shares of the company’s stock worth $661,000 after buying an additional 52,830 shares during the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.